HyaMab, based in the Pharmaceutical Valley of Zhangjiang Innovation Cluster, is committed to novel anti-cancer therapeutics including monoclonal antibodies (mAbs), allogenic NK cells, and CAR-engineered NK / T cells with best-in-class and/or first-in-class (BIC/FIC) potentials. Working closely with international leading research laboratories such as Intelligent Medicine, Shanghai Institute for Advanced Immunochemical Studies (SIAIS) / ShanghaiTech University, as well as industrial R&D partners, HyaMab has established a comprehensive pipeline covering from discovery leads with novel mode-of-action (MoA) (e.g. NKp46, NKG2D, MICA/B, CD16, etc.) to clinical-stage development candidates (e.g. 4-1BB, NKG2A, etc.).
HyaMab’s strategy is to harness the power of innate immunity (especially NK cells) to combat and stop the proliferation and metastasis of cancer cells. The two focal areas of HyaMab R&D are to develop 1) antibody modulators and 2) engineered immune cells that enhance and sustain the natural killing activity of circulating NK cells. The company continues to build its core competence in immunoncology (IO) with the backing of a proprietary technology platform.
Aiming at original innovation and high international standards, HyaMab vigorously pursues excellence in every aspect of drug discovery and development. To keep and gain more competitive edge, HyaMab actively implements and optimizes its intellectual property (IP) coverage on key products and technologies. A total of 12 patents / patent applications have been granted and filed. More importantly, HyaMab has a leadership core team consisting of people with strong expertise and successful track-records in drug discovery, biotechnology enabling, and business development.